Merck & Co., Inc.

MRK · NYSE

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▼ 0.0% below current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.1%

Institutions82.7%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$65.01B	$64.17B	$60.12B	$59.28B	$48.70B	$47.99B	$46.84B	$42.29B	$40.12B	$39.81B
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$16.38B	$15.19B	$16.13B	$17.41B	$13.63B	$15.48B	$14.11B	$13.51B	$12.78B	$13.89B
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$9.00M	$16.00M	$365.00M	$14.52B	$13.05B	$15.00M	-$66.00M	$6.22B	$2.39B	$3.92B
Net income divided by the number of shares outstanding — profit attributable to each share.	$7.30	$6.76	$0.14	$5.73	$5.16	$2.79	$3.84	$2.00	$0.00	$1.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$7.28	$6.74	$0.14	$5.71	$5.14	$2.78	$3.81	$2.00	$0.00	$1.00

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$14.56B	$13.24B	$6.84B	$12.69B	$8.10B	$8.06B	$9.68B	$7.96B	$6.09B	$6.51B
Everything the company owns that has value — cash, property, inventory, investments, and more.	$136.87B	$117.11B	$106.67B	$109.16B	$105.69B	$91.59B	$84.40B	$82.64B	$87.87B	$95.38B
All of the company's interest-bearing borrowings, short and long term combined.	$49.34B	$37.11B	$35.05B	$30.69B	$33.10B	$31.79B	$26.35B	$25.11B	$24.41B	$24.84B
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$52.61B	$46.31B	$37.58B	$45.99B	$38.18B	$25.32B	$25.91B	$26.70B	$34.34B	$40.09B

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$16.47B	$21.47B	$13.01B	$19.09B	$13.12B	$10.25B	$13.44B	$10.92B	$6.45B	$10.38B
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$4.11B	$3.37B	$3.86B	$4.39B	$4.45B	$4.68B	$3.47B	$2.62B	$1.89B	$1.61B
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	$12.36B	$18.10B	$9.14B	$14.71B	$8.67B	$5.57B	$9.97B	$8.31B	$4.56B	$8.76B

	You	Peer avg
P/E	120.3	30.7
Revenue Growth	+5.1%	+15.7%
ROE	7.0%	44.9%

Merck & Co., Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison